Research programme: nanoparticle therapeutics - NanoProteagen

Drug Profile

Research programme: nanoparticle therapeutics - NanoProteagen

Alternative Names: Nanoxane™; NPG-114; NPG-215; NPG-384

Latest Information Update: 09 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NanoProteagen
  • Class Cytokine genes; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Cytokine stimulants; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Cancer

Most Recent Events

  • 09 Sep 2016 Preclinical trials in Breast cancer (Metastatic disease, Second-line therapy or greater) in USA (unspecified route) before September 2016
  • 09 Sep 2016 Preclinical trials in Cancer in USA (unspecified route) before September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top